Media & Publications
In the News
What happens in Swedish virus research?
The Bridge & Medicon Village arranged a #iställetföralmedalen digital event on work & health. https://altitudemeetings.se/jobb-halsa/ Amniotics CEO Kåre Engilde participated in discussions on Swedish virus research. https://vimeo.com/431809235
Hopes to cure Covid-19 with stem cells – takes in 25 million SEK
Amniotics chairman Christer Fåhraeus was recently featured in Dagens Industri. The 25 million SEK that Amniotics now takes in venture capital will be enough to investigate the possibility of using the technology against Covid-19."We intended to use stem cells for a...
Amniotics is featured on TV4 for their novel source of MSCs to treat COVID-19
https://www.mediconvillage.se/sv/amniotics-featured-tv4-their-novel-source-mscs-treat-covid-19 Amniotics was recently featured in Swedish TV4, in regard to development of our cell-therapeutic for COVID-19 diseases. Studies have shown that mesenchymal stem cells can...
Unique stem cells from amniotic fluid (article in Swedish)
The biotech company Amniotics has developed technologies for extracting and refining amniotic fluid stem cells for cutting-edge therapy methods. In 2020, the company will enter the clinical phase, which may lead to a breakthrough in future cell therapies. https://www.di.se/brandstudio/amniotics/unika-stamceller-ur-fostervatten/
Svenskt biotechbolag nära genombrott i behandling mot covid-19 – söker investerare
Researchers at the biotech company Amniotics in Lund has developed a lung specific stem cell for treatment of covid-19. The market for treating lung- and airway diseases is valued at 47 billion Euro. – At present, we are working day and night to finish our process...
Nio projekt för medicin och vaccin mot covid-19 pågår i Medicon Valley. Ett är Amniotics lungspecifika stamceller mot covid-19.
https://www.newsoresund.se/coronaprojekt-medicon-valley/
Press Releases
Amniotics to Present at the Upcoming 2020 Virtual European Biotech Investor Day 2020
Kåre Engkilde, Chief Executive Officer, plans to present an overview of the company and provide a business update at the upcoming Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq. During the 30 (public...
Longboat Amniotics AB has changed its name to Amniotics AB
Longboat Amniotics AB has changed its name to Amniotics AB, to emphasize our commitment to developing innovative and life-changing treatments based on our cell-based products from amniotic fluid. Our pipeline of cell-therapeutics is based on Mesenchymal Stem Cell,...
Longboat Amniotics AB recruits a new CEO in Kåre Engkilde, PhD
The Board of Longboat Amniotics announces a change of CEO in the company as from June 1st. Kåre Engkilde, PhD Immunology, currently working for Agilent Technologies in Denmark where he is Development Manager, Clinical & Medical Affairs, is appointed as Longboat’s...
Fast Development in Longboat Explorers AB
Fast Development in Longboat Explorers AB In March, Longboat Explorers AB has graduated from the Incubator Environment of SmiLe in Lund and it has become “Alumni”. This is in recognition of the company’s fast development from the initial development phase to a...
The CEO of Longboat Explorers, Anders Månsson, is invited for a panel debate on the future of Swedish Life Science
The CEO of Longboat Explorers, Anders Månsson, is invited to and will participate, December 5. 2017, in "Life Science dagen" (Life Science Day) in Stockholm hosted by the leading Swedish Business paper "Dagens Industri" and the leading Life Science paper "Dagens...
New scientific publication underpins Longboat’s Business Model
Recently a peer reviewed article was published in Stem Cell Research & Therapy (see link below) that underpins the intended business model of Longboat Explorers AB. The article concludes that Mesenchymal Stem Cells (sometimes also referred to as Mesenchymal...